Actinium Pharmaceuticals Inc. (ATNM) NYSE MKT LLC

$7.38 0.18 (2.50%)

Market Cap: $185.86M

As of 09/30/22 04:00 PM EDT. Market closed.

(ATNM)

Actinium Pharmaceuticals Inc. (ATNM) NYSE MKT LLC

$7.38 0.18 (2.50%)

Market Cap: $185.86M

As of 09/30/22 04:00 PM EDT. Market closed.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for its ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to ... read more

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for its ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With its ARC approach, Actinium seeks to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Its lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. More information on this Phase 3 clinical trial can be found at sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center and Phase 1/2 anti-HIV stem cell gene therapy with UC Davis. In addition, the company is developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Ongoing combination trials include its CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax. Underpinning its clinical programs is its proprietary AWE (Antibody Warhead Enabling) technology platform. This is where its intellectual property portfolio of over 100 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster its pipeline for strategic purposes. Its AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Sandesh Seth
Full Time Employees
32
URL
Address
275 Madison Ave Fl 7, New York, New York, 10016-1101.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Sandesh Seth
Full Time Employees
32
Address
275 Madison Ave Fl 7, New York, New York, 10016-1101.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$7.35
Previous Close
$7.20
Days Range
$7.11 - $7.63
52 week range
$4.41 - $9.21
Volume
134,650
Avg. Volume (30 days)
167,083
Market Cap
$185.86M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
25,184,654
Open
$7.35
Previous Close
$7.20
Days Range
$7.11 - $7.63
52 week range
$4.41 - $9.21
Volume
134,650
Avg. Volume (30 days)
167,083
Market Cap
$185.86M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
25,184,654

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR ACTINIUM PHARMACEUTICALS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Berger Mark Stanley Chief Medical Officer Mar 05, 2019 Option Exercise $0.60 3,500 2,100 22,500 Mar 07, 2019, 04:15 PM
SETH SANDESH Chairman & CEO Feb 21, 2019 Option Exercise $0.60 8,125 4,875 161,458 Feb 21, 2019, 04:45 PM
SETH SANDESH Chairman & CEO Dec 10, 2018 Buy $0.44 10,000 4,372 153,333 Dec 10, 2018, 04:14 PM
O'Loughlin Steve Principal Financial Officer Dec 10, 2018 Buy $0.44 10,000 4,350 35,500 Dec 10, 2018, 04:10 PM
Ludwig Dale L. Chief Scientific Officer Nov 19, 2018 Buy $0.45 10,000 4,499 10,000 Nov 20, 2018, 05:08 PM
SETH SANDESH CEO Jul 17, 2018 Buy $0.79 10,000 7,900 143,333 Jul 17, 2018, 05:13 PM
O'Loughlin Steve Principal Financial Officer Jun 15, 2018 Buy $0.50 12,000 6,000 25,500 Jun 15, 2018, 06:08 PM
SETH SANDESH Chairman & CEO Apr 19, 2018 Buy $0.38 5,000 1,900 133,333 Apr 20, 2018, 04:15 PM
Berger Mark Stanley Chief Medical Officer Mar 06, 2018 Option Exercise $0.50 14,000 7,000 19,000 Mar 19, 2018, 05:04 PM
SETH SANDESH Chairman & CEO Mar 06, 2018 Option Exercise $0.50 52,500 26,250 128,333 Mar 08, 2018, 04:35 PM
Ray Nitya G. Executive VP Mar 06, 2018 Option Exercise $0.50 10,000 5,000 20,000 Mar 08, 2018, 04:32 PM
Steinhart Richard I Director Mar 06, 2018 Option Exercise $0.50 7,000 3,500 9,500 Mar 08, 2018, 04:24 PM
O'Loughlin Steve Principal Financial Officer Mar 06, 2018 Option Exercise $0.50 10,000 5,000 13,500 Mar 08, 2018, 04:20 PM
Shetty Ajit Director Feb 28, 2018 Buy $0.43 22,730 9,774 22,730 Mar 01, 2018, 07:08 AM
SETH SANDESH Chairman & CEO Aug 02, 2017 Buy $0.75 33,333 25,000 75,833 Aug 04, 2017, 04:35 PM
Ray Nitya G. Executive Vice President Aug 02, 2017 Buy $0.75 10,000 7,500 10,000 Aug 04, 2017, 04:22 PM
Berger Mark Stanley Chief Medical Officer Jun 15, 2017 Buy $1.11 5,000 5,550 5,000 Jun 15, 2017, 04:56 PM
SETH SANDESH Chairman and CEO Jun 15, 2017 Buy $1.16 7,500 8,725 42,500 Jun 15, 2017, 04:54 PM
O'Loughlin Steve Principal Financial Officer Jun 15, 2017 Buy $1.17 3,500 4,095 3,500 Jun 15, 2017, 04:51 PM
SETH SANDESH Executive Chairman Dec 30, 2016 Buy $0.88 5,000 4,400 35,000 Jan 03, 2017, 08:00 AM
SETH SANDESH Executive Chairman Dec 12, 2016 Buy $0.98 5,000 4,900 30,000 Dec 12, 2016, 04:44 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Aug 31, 2016 Sale $1.83 136,853 251,118 4,821,226 Sep 01, 2016, 05:01 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Aug 30, 2016 Sale $1.81 56,074 101,254 4,878,988 Sep 01, 2016, 05:01 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Aug 29, 2016 Sale $1.72 25,000 42,875 4,914,988 Aug 30, 2016, 05:07 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Aug 26, 2016 Sale $1.70 25,000 42,620 4,939,490 Aug 30, 2016, 05:07 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Aug 16, 2016 Sale $1.72 5,029 8,652 4,952,888 Aug 17, 2016, 04:05 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Aug 15, 2016 Sale $1.72 4,439 7,635 4,957,517 Aug 17, 2016, 04:05 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jul 12, 2016 Sale $1.80 3,100 5,581 4,962,056 Jul 14, 2016, 04:29 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jul 11, 2016 Sale $1.80 800 1,440 4,965,056 Jul 12, 2016, 05:11 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jul 08, 2016 Sale $1.80 21,190 38,142 4,965,856 Jul 12, 2016, 05:11 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jul 06, 2016 Sale $1.80 10,500 18,900 4,987,046 Jul 07, 2016, 04:24 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jul 05, 2016 Sale $1.82 10,340 18,862 5,001,886 Jul 07, 2016, 04:24 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jun 30, 2016 Sale $1.80 19,150 34,539 5,140,786 Jul 05, 2016, 04:36 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jul 01, 2016 Sale $1.81 128,950 233,897 5,091,995 Jul 05, 2016, 04:36 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jun 15, 2016 Sale $1.90 33,619 63,876 5,155,986 Jun 17, 2016, 04:35 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jun 02, 2016 Sale $2.01 17,790 35,716 5,196,395 Jun 06, 2016, 07:20 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Jun 01, 2016 Sale $2.09 40,114 83,838 5,242,709 Jun 02, 2016, 04:21 PM
Memorial Sloan-Kettering Cancer Center 10% Owner May 31, 2016 Sale $1.93 129,336 249,547 5,358,735 Jun 02, 2016, 04:21 PM
Memorial Sloan-Kettering Cancer Center 10% Owner May 26, 2016 Sale $1.92 40,068 77,061 5,389,745 May 31, 2016, 06:58 PM
Memorial Sloan-Kettering Cancer Center 10% Owner May 25, 2016 Sale $1.90 36,400 69,235 5,427,313 May 26, 2016, 05:43 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Apr 26, 2016 Sale $1.96 6,500 12,725 5,455,813 Apr 26, 2016, 05:25 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Apr 25, 2016 Sale $2.02 18,385 37,204 5,476,398 Apr 26, 2016, 05:25 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Apr 22, 2016 Sale $2.07 27,692 57,336 5,502,849 Apr 26, 2016, 05:25 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Apr 20, 2016 Sale $2.03 33,497 68,042 5,551,787 Apr 21, 2016, 04:56 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Apr 19, 2016 Sale $2.03 150,000 304,321 5,652,878 Apr 21, 2016, 04:56 PM
Memorial Sloan-Kettering Cancer Center 10% Owner Apr 21, 2016 Sale $2.04 13,000 26,557 5,509,590 Apr 21, 2016, 04:56 PM
Nicholson, C. David Director Apr 14, 2016 Buy $2.00 5,000 10,000 15,000 Apr 18, 2016, 05:28 PM
DAVE KAUSHIK J CEO and Interim CFO Apr 14, 2016 Buy $2.02 10,000 20,180 88,500 Apr 18, 2016, 05:27 PM
SETH SANDESH Director Apr 15, 2016 Buy $2.00 3,500 7,015 18,500 Apr 18, 2016, 05:26 PM
SETH SANDESH Director Apr 14, 2016 Buy $2.00 5,000 10,000 15,000 Apr 18, 2016, 05:26 PM
SETH SANDESH Director Apr 18, 2016 Buy $1.98 6,500 12,885 25,000 Apr 18, 2016, 05:26 PM
Steinhart Richard I Director Apr 14, 2016 Buy $2.01 2,500 5,025 2,500 Apr 18, 2016, 05:24 PM
TRAVERSA SERGIO Director Apr 15, 2016 Buy $2.02 1,000 2,020 3,000 Apr 18, 2016, 05:24 PM
TRAVERSA SERGIO Director Apr 14, 2016 Buy $2.02 2,000 4,040 2,000 Apr 18, 2016, 05:24 PM
DAVE KAUSHIK J President, CEO and Interim CFO May 07, 2015 Option Exercise $2.45 120,501 295,227 85,583 May 22, 2015, 05:08 PM
DAVE KAUSHIK J President, CEO and Interim CFO May 07, 2015 Option Exercise $2.45 35,583 87,178 85,583 May 22, 2015, 05:08 PM
CICIC DRAGAN COO and Chief Medical Officer May 07, 2015 Option Exercise $2.52 2,380 5,998 560 May 22, 2015, 05:07 PM
CICIC DRAGAN COO and Chief Medical Officer May 07, 2015 Option Exercise $2.52 560 1,411 560 May 22, 2015, 05:07 PM
CICIC DRAGAN COO and Chief Medical Officer Feb 21, 2014 Option Exercise $5.55 3,500 19,425 3,500 Mar 16, 2015, 05:26 PM
SETH SANDESH Director Aug 08, 2013 Option Exercise $3.60 10,000 36,000 0 Dec 24, 2013, 03:43 PM
TRAVERSA SERGIO Interim CFO Aug 08, 2013 Option Exercise $3.60 10,000 36,000 0 Dec 24, 2013, 03:41 PM
MAZANET ROSEMARY Director May 15, 2013 Buy $3.95 100 395 100 May 22, 2013, 08:04 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Berger Mark Stanley Chief Medical Officer 03/05/2019 2,100
SETH SANDESH Chairman & CEO 02/21/2019 4,875
SETH SANDESH Chairman & CEO 12/10/2018 4,372
O'Loughlin Steve Principal Financial Officer 12/10/2018 4,350
Ludwig Dale L. Chief Scientific Officer 11/19/2018 4,499
SETH SANDESH CEO 07/17/2018 7,900
O'Loughlin Steve Principal Financial Officer 06/15/2018 6,000
SETH SANDESH Chairman & CEO 04/19/2018 1,900
Berger Mark Stanley Chief Medical Officer 03/06/2018 7,000
SETH SANDESH Chairman & CEO 03/06/2018 26,250
Ray Nitya G. Executive VP 03/06/2018 5,000
Steinhart Richard I Director 03/06/2018 3,500
O'Loughlin Steve Principal Financial Officer 03/06/2018 5,000
Shetty Ajit Director 02/28/2018 9,774
SETH SANDESH Chairman & CEO 08/02/2017 25,000
Ray Nitya G. Executive Vice President 08/02/2017 7,500
Berger Mark Stanley Chief Medical Officer 06/15/2017 5,550
SETH SANDESH Chairman and CEO 06/15/2017 8,725
O'Loughlin Steve Principal Financial Officer 06/15/2017 4,095
SETH SANDESH Executive Chairman 12/30/2016 4,400
SETH SANDESH Executive Chairman 12/12/2016 4,900
Memorial Sloan-Kettering Cancer Center 10% Owner 08/31/2016 251,118
Memorial Sloan-Kettering Cancer Center 10% Owner 08/30/2016 101,254
Memorial Sloan-Kettering Cancer Center 10% Owner 08/29/2016 42,875
Memorial Sloan-Kettering Cancer Center 10% Owner 08/26/2016 42,620
Memorial Sloan-Kettering Cancer Center 10% Owner 08/16/2016 8,652
Memorial Sloan-Kettering Cancer Center 10% Owner 08/15/2016 7,635
Memorial Sloan-Kettering Cancer Center 10% Owner 07/12/2016 5,581
Memorial Sloan-Kettering Cancer Center 10% Owner 07/11/2016 1,440
Memorial Sloan-Kettering Cancer Center 10% Owner 07/08/2016 38,142
Memorial Sloan-Kettering Cancer Center 10% Owner 07/06/2016 18,900
Memorial Sloan-Kettering Cancer Center 10% Owner 07/05/2016 18,862
Memorial Sloan-Kettering Cancer Center 10% Owner 06/30/2016 34,539
Memorial Sloan-Kettering Cancer Center 10% Owner 07/01/2016 233,897
Memorial Sloan-Kettering Cancer Center 10% Owner 06/15/2016 63,876
Memorial Sloan-Kettering Cancer Center 10% Owner 06/02/2016 35,716
Memorial Sloan-Kettering Cancer Center 10% Owner 06/01/2016 83,838
Memorial Sloan-Kettering Cancer Center 10% Owner 05/31/2016 249,547
Memorial Sloan-Kettering Cancer Center 10% Owner 05/26/2016 77,061
Memorial Sloan-Kettering Cancer Center 10% Owner 05/25/2016 69,235
Memorial Sloan-Kettering Cancer Center 10% Owner 04/26/2016 12,725
Memorial Sloan-Kettering Cancer Center 10% Owner 04/25/2016 37,204
Memorial Sloan-Kettering Cancer Center 10% Owner 04/22/2016 57,336
Memorial Sloan-Kettering Cancer Center 10% Owner 04/20/2016 68,042
Memorial Sloan-Kettering Cancer Center 10% Owner 04/19/2016 304,321
Memorial Sloan-Kettering Cancer Center 10% Owner 04/21/2016 26,557
Nicholson, C. David Director 04/14/2016 10,000
DAVE KAUSHIK J CEO and Interim CFO 04/14/2016 20,180
SETH SANDESH Director 04/15/2016 7,015
SETH SANDESH Director 04/14/2016 10,000
SETH SANDESH Director 04/18/2016 12,885
Steinhart Richard I Director 04/14/2016 5,025
TRAVERSA SERGIO Director 04/15/2016 2,020
TRAVERSA SERGIO Director 04/14/2016 4,040
DAVE KAUSHIK J President, CEO and Interim CFO 05/07/2015 295,227
DAVE KAUSHIK J President, CEO and Interim CFO 05/07/2015 87,178
CICIC DRAGAN COO and Chief Medical Officer 05/07/2015 5,998
CICIC DRAGAN COO and Chief Medical Officer 05/07/2015 1,411
CICIC DRAGAN COO and Chief Medical Officer 02/21/2014 19,425
SETH SANDESH Director 08/08/2013 36,000
TRAVERSA SERGIO Interim CFO 08/08/2013 36,000
MAZANET ROSEMARY Director 05/15/2013 395
Load More Insider Transactions